Clinical trial · Observational
Study of Use of CTC in NSCLC
The Use of Circulating Tumor Cells in Non-Small Cell Lung Cancer: Novel Isolation Methods and Clinical Applications
NCT01990651CI-TRIAL-00012703unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess whether the detection of circulating tumor cells (CTC) could be used as a tool to earlier diagnose, more accurately predict treatment response / failure and predict overall survival in non-small cell lung cancer (NSCLC) patients
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Obstructive Pulmonary Disease | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- To estimate the correlation between the number of circulating tumor cells (CTC) and clinical stage of the disease
- timeFrame
- Completed within 6 months of the last sample collected
- measure
- In Stage I, II or III patients with resectable disease, to obtain preliminary data to assess whether the number of CTC in post operative peripheral blood samples decrease compared with the number of CTC in the pre operative peripheral blood samples
- timeFrame
- Measured up to 12 week post op
- measure
- To obtain preliminary data to assess whether lower numbers of CTC are associated with a reduction in tumor burden (by RECIST criteria) on imaging
- timeFrame
- Completed within 6 months of the last sample collected
- measure
- To obtain preliminary data to assess whether there is a decrease in the number of CTC during treatment with chemotherapy in Stage IV disease
- timeFrame
- measured up to completion of 4 cycles of chemo or up to 12 weeks after completion of radiation and chemo treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: For subjects with lung malignancies: * 18 years of age and older * Diagnosis of new or recurrent non-small cell lung cancer * Awaiting treatment and follow up * Have radiographic measurable metastatic disease that can be followed * Be able to sign an IRB approved informed consent form * Life expectancy greater than 12 weeks For subjects with COPD and without lung malignancies: * 18 years of age and older * Diagnosis of COPD * No current or prior malignancies (except squamous or basal cell carcinoma of the skin) * Be able to sign an IRB approved informed consent form For Healthy Control Subjects (Dry Runs): * 18 years of age and older * Has no current or prior malignancies (except squamous or basal cell carcinoma of the skin) * Patients must sign an IRB approved informed consent form Exclusion Criteria: For subjects with lung malignancies: * Have other concurrent lung cancer malignancies, or any other form of malignancy (except squamous or basal cell carcinoma of the skin) * ECOG performance status of 4 * Pregnant female (self-reporting) * Cognitively Impaired * Prisoner For subjects with COPD and without lung malignancies and Healthy Controls: * Any other form of malignancy (except squamous or basal cell carcinoma of the skin) * Pregnant female (self reporting) * Cognitively impaired * Prisoner
References
Publications (0)
Data not yet available
No reference posted for this study.